{"date":"2026-09-20","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6499-2026-09-20-2338-169q9ae","company_id":"6499","company":"益安","market":"上櫃","industry":"生技醫療","date":"2026-09-20","time":"23:38:41","subject":"本公司與Terumo簽訂Cross-Seal和解暨終止協議","clause":"第53款","fact_date":"2026-09-20","cite_as":"公開資訊觀測站重大訊息：益安（6499），2026-09-20 23:38，「本公司與Terumo簽訂Cross-Seal和解暨終止協議」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2026-09-20-0045-1tdqjyk","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2026-09-20","time":"00:45:44","subject":"代子公司天津紅日健達康醫藥科技有限公司PTS治療肝細胞癌中國第二期臨床試驗研究摘要獲ESMO AsiaCongress2026接受發表","clause":"第53款","fact_date":"2026-09-19","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2026-09-20 00:45，「代子公司天津紅日健達康醫藥科技有限公司PTS治療肝細胞癌中國第二期臨床試驗研究摘要獲ESMO AsiaCongress2」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}